Jayendrakumar Patel, MD
Interventional Cardiology · Clearwater, FLNPI 1760703318
Payments from drug & device makers
Across 275 payments — averaging $88.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$15K
- Edwards Lifesciences$3K
- Abbott$2K
- Novartis$484
- Abiomed$477
- Philips North America LLC$417
- plus $3K from 24 others
What the payments were for
- Speaking & faculty fees$7,68832%
- Travel & lodging$7,30030%
- Food & beverage$9,30338%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 75 | $14,549 |
| Edwards Lifesciences | 23 | $3,152 |
| Abbott | 33 | $2,202 |
| Novartis | 20 | $484 |
| Abiomed | 10 | $477 |
| Philips North America LLC | 3 | $417 |
| AstraZeneca | 16 | $382 |
| Boston Scientific | 10 | $324 |
| Amgen | 19 | $308 |
| Pfizer | 17 | $307 |
| Shockwave Medical, Inc | 3 | $248 |
| Jenavalve Technology, Inc. | 3 | $245 |
| Boehringer Ingelheim | 8 | $179 |
| Inari Medical, Inc. | 1 | $152 |
| Opsens Inc. | 3 | $141 |
| Biotronik Inc. | 1 | $128 |
| Lexicon Pharmaceuticals, Inc. | 5 | $110 |
| Scpharmaceuticals Inc. | 4 | $94 |
| Novo Nordisk | 4 | $89 |
| Johnson & Johnson | 4 | $82 |
| E.r. Squibb & Sons, L.L.C. | 3 | $54 |
| Cardiovascular Systems Inc. | 2 | $26 |
| Actelion Pharmaceuticals US, Inc. | 1 | $25 |
| Sanofi-aventis U.S. LLC | 1 | $23 |
| Penumbra, Inc. | 1 | $17 |
| Biosense Webster, Inc. | 1 | $17 |
| Vital Connect, Inc | 1 | $17 |
| Bayer | 1 | $16 |
| Angiodynamics, Inc. | 1 | $16 |
| Teleflex LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- COREVALVE EVOLUT R$11,128
- EVOQUE$1,229
- CoreValve Evolut$790
- PASCAL$753
- Edwards SAPIEN 3 Transcatheter Heart Valve$421
- US Und$365
- MitraClip System$240
- Impella$229
- JenaValve Pericardial TAVR System$191
- FLOWTRIEVER CATHETER, S$152
- CT THROMBECTOMY SYSTEM KIT$152
- MitraClip$147
- Resolute$131
- ENTRESTO$125
- FARXIGA$125
- TRICLIP$122
- Mitra Clip system$107
How this compares
$24,291 in reported general payments places this provider in the 70th percentile of 623 interventional cardiology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 219 | $231,009 |
| XareltoRivaroxaban | 77 | $90,721 |
| BrilintaTicagrelor | 85 | $59,723 |
| JardianceEmpagliflozin | 72 | $59,182 |
| Repatha SureclickEvolocumab | 55 | $53,347 |
| FarxigaDapagliflozin Propanediol | 33 | $24,653 |
| EntrestoSacubitril/Valsartan | 23 | $22,385 |
| Rosuvastatin Calcium | 400 | $4,222 |
| Metoprolol Succinate | 223 | $3,238 |
| ClopidogrelClopidogrel Bisulfate | 186 | $2,195 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 12 | $1,943 |
| Amiodarone Hcl | 38 | $1,877 |
| Atorvastatin Calcium | 119 | $1,623 |
| Ezetimibe | 49 | $1,101 |
| Amlodipine Besylate | 167 | $1,068 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $307 | $231,009219 claims |
| Johnson & JohnsonXarelto | $82 | $90,72177 claims |
| AstraZenecaBrilinta, Farxiga | $382 | $84,376118 claims |
| Boehringer IngelheimJardiance | $179 | $59,18272 claims |
| NovartisEntresto | $484 | $22,38523 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 623 interventional cardiology providers in Florida.
Other interventional cardiology in Clearwater
- Douglas SpriggsClearwater$3.2M
- Syed GilaniClearwater$511K
- Bernardo SteinClearwater$337K
- Dominick AngiolilloJacksonville$4M
- Rakesh PrashadOcala$3.1M
- Aldo Martinez FleitesMiami Lakes$2.2M
- Rohit AminPensacola$2M
- Roberto CubedduNaples$2M
- Arthur LeeGainesville$2M
- Ruby SatpathyJacksonville$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.